Does EVOLOCUMAB Cause Glycosylated haemoglobin increased? 388 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 388 reports of Glycosylated haemoglobin increased have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.3% of all adverse event reports for EVOLOCUMAB.
388
Reports of Glycosylated haemoglobin increased with EVOLOCUMAB
0.3%
of all EVOLOCUMAB reports
1
Deaths
11
Hospitalizations
How Dangerous Is Glycosylated haemoglobin increased From EVOLOCUMAB?
Of the 388 reports, 1 (0.3%) resulted in death, 11 (2.8%) required hospitalization, and 1 (0.3%) were considered life-threatening.
Is Glycosylated haemoglobin increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 388 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Glycosylated haemoglobin increased?
DULAGLUTIDE (2,691)
INSULIN GLARGINE (2,649)
INSULIN LISPRO (2,482)
METFORMIN (1,539)
INSULIN HUMAN (1,008)
EXENATIDE (921)
SEMAGLUTIDE (818)
EMPAGLIFLOZIN (743)
TIRZEPATIDE (555)
INSULIN ASPART (550)
Which EVOLOCUMAB Alternatives Have Lower Glycosylated haemoglobin increased Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE